Skip to main content
OpenTrials
Completed

NCT Number: NCT01124942

MGuard Stent in ST-elevation Myocardial Infarction

The Investigators will test the hypothesis that MGuard net protective stent, the investigational device, would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent percutaneous coronary interventions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Federico II University of Naples

Naples, 80131, Italy

About this study

Embolization of thrombotic debris still represents a complication for ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary interventions (PCI).

Distal embolization may decrease coronary and myocardial reperfusion after PCI in STEMI setting.

Unfortunately, intracoronary filters present several important limitations limiting their use and their efficacy especially in presence of huge amount of thrombus. In this respect, recent trials investigated whether a default manual thrombectomy strategy before stenting would ameliorate angiographic as well as clinical outcomes for STEMI patients undergoing percutaneous revascularization.

Of note, the most of embolization occurs when guidewire, and thrombectomy device cross the thrombus, and after the stent has been implanted as a consequence of plaque prolapse through the stent struts.

MGuard net protective stent, the investigational device, is a bare-metal stent covered with a ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, that is anchored to the external surface of the struts. This biocompatible fiber net (string diameter 10-22 μm) has minimal effects on the stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net and isolating the prothrombotic intima components from the blood stream.

This protocol will test the hypothesis that MGuard stent would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent PCI in terms of angiographic as well as clinical outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >/= 18-year-old patients, willing to participate the study, after informed consent signature
  • Female not pregnant or potentially child-bearing
  • > 1 mV ST segment elevation in two or more contiguous leads
  • Acute MI lasting more than 30 minutes and less than 12 hours
  • De novo acute MI
  • Infarct related artery reference vessel diameter >/= 2.5 mm
  • Patient suitable for stenting according to vessel and lesion features

Exclusion criteria

  • Dual antiplatelet therapy contraindication
  • Ischemic stroke less than 30 days or previous haemorrhagic stroke
  • WBC count less than 1000 per mm3;
  • Platelet count less than 50.000 per mm3
  • Life expectancy less than 1 year
  • Cardiogenic shock at admission
  • Previous stented infarct related artery
  • Stent thrombosis as the responsible for current STEMI
  • Inability to identify infarct related artery
  • True bifurcation lesion, or lesion near a side branch with a reference vessel diameter >/= 2.5 mm that could be diseased after stenting procedure
  • LBBB
  • Definitive pacing (or ECG abnormalities precluding ST-segment resolution evaluation
  • Participation other study

Treatment and study plan

MGuard net protective coronary stent

Device

It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.

Other names: MGuard net protective stent

Bare-metal stent and manual thrombectomy device

Device

Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent

Primary outcomes

  1. Number of patients with Myocardial Perfusional Blush Grade 2-3

    Time frame: 30 minutes after revascularization

    Myocardial Perfusional Blush Grade 2-3 at the end of the procedure

Secondary outcomes

  1. Number of MACE

    Time frame: 1 month

    Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.

  2. Complete ST-segment resolution

    Time frame: 60 minutes after revascularization

    Complete (>70%) ST-segment resolution at 60 minutes post-revascularization

  3. Thrombolysis in myocardial infarction antegrade coronary flow

    Time frame: 30 minutes after revascularization

    TIMI coronary flow at the end of the procedure

  4. Corrected TIMI Frame count

    Time frame: 30 minutes after revascularization

    Corrected TIMI Frame count at the end of the procedure

  5. Infarct related area reduction and left ventricular ejection fraction recovery

    Time frame: 6 months

    Six-month infarct related area reduction and left ventricular ejection fraction recovery as compared with infarct related area and and left ventricular ejection fraction at admission.

  6. Procedural device performance

    Time frame: 60 minutes after revascularizationl

    Device performance evaluated during the procedure in terms of pushability, trackability, crossability and deliverability

  7. Number of MACE

    Time frame: 6 months

    Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.

  8. Number of MACE

    Time frame: 12 months

    Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.

Sponsors and collaborators

Lead sponsor

Federico II University

Other

Registry information

Official study title

MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial

Acronym: GUARDIAN

Important dates

Study start
2010
Primary completion
2011
Study completion
2013
First posted
May 18, 2010
Registry last updated
Mar 31, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.